2024

Heggie, Robert, Jaiswal, Nishant ORCID: https://orcid.org/0000-0001-5511-4572, McCartney, Elaine ORCID: https://orcid.org/0000-0002-0260-4161, Moss, Jon, Menne, Tobias, Jones, Brian, Boyd, Kathleen ORCID: https://orcid.org/0000-0002-9764-0113, Soulis, Eileen, Hawkins, Neil ORCID: https://orcid.org/0000-0003-3199-221X and Wu, Olivia ORCID: https://orcid.org/0000-0002-0570-6016 (2024) Central venous access devices for the delivery of systemic anticancer therapy: an economic evaluation. Value in Health, 27(1), pp. 7-14. (doi: 10.1016/j.jval.2023.09.2996) (PMID:37844662)

2023

Crabb, S. J. et al. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41(1), pp. 54-64. (doi: 10.1200/JCO.22.00405) (PMID:35960902) (PMCID:PMC9788980)

2021

Moss, J. G. et al. (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet, 398(10298), pp. 403-415. (doi: 10.1016/S0140-6736(21)00766-2) (PMID:34297997)

Wu, O. et al. (2021) Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT. Health Technology Assessment, 25(47), (doi: 10.3310/hta25470)

2020

Fulton, B. et al. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, 344. (doi: 10.1186/s13063-020-04283-5) (PMID:32306987) (PMCID:PMC7168999)

2016

Graham, J.S., Boyd, K. ORCID: https://orcid.org/0000-0002-9764-0113, Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. ORCID: https://orcid.org/0000-0002-4175-914X (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, 161. (doi: 10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)

Articles

Heggie, Robert, Jaiswal, Nishant ORCID: https://orcid.org/0000-0001-5511-4572, McCartney, Elaine ORCID: https://orcid.org/0000-0002-0260-4161, Moss, Jon, Menne, Tobias, Jones, Brian, Boyd, Kathleen ORCID: https://orcid.org/0000-0002-9764-0113, Soulis, Eileen, Hawkins, Neil ORCID: https://orcid.org/0000-0003-3199-221X and Wu, Olivia ORCID: https://orcid.org/0000-0002-0570-6016 (2024) Central venous access devices for the delivery of systemic anticancer therapy: an economic evaluation. Value in Health, 27(1), pp. 7-14. (doi: 10.1016/j.jval.2023.09.2996) (PMID:37844662)

Crabb, S. J. et al. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41(1), pp. 54-64. (doi: 10.1200/JCO.22.00405) (PMID:35960902) (PMCID:PMC9788980)

Moss, J. G. et al. (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet, 398(10298), pp. 403-415. (doi: 10.1016/S0140-6736(21)00766-2) (PMID:34297997)

Wu, O. et al. (2021) Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT. Health Technology Assessment, 25(47), (doi: 10.3310/hta25470)

Fulton, B. et al. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, 344. (doi: 10.1186/s13063-020-04283-5) (PMID:32306987) (PMCID:PMC7168999)

Graham, J.S., Boyd, K. ORCID: https://orcid.org/0000-0002-9764-0113, Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F. and Evans, T. ORCID: https://orcid.org/0000-0002-4175-914X (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, 161. (doi: 10.1186/s13104-015-1778-4) (PMID:26969121) (PMCID:PMC4788848)